PHASE 2 NIVO-ALCL STUDY OF NIVOLUMAB FOR RELAPSE/REFRACTORY ALK+ALCL, FOR PATIENTS WITH PROGRESSIVE DISEASE OR AS CONSOLIDATIVE IMMUNOTHERAPY AFTER COMPLETE REMISSION

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research Pub Date : 2025-09-01 DOI:10.1016/j.leukres.2025.107986

Charlotte Rigaud, Nusaibah Ibrahimi, David Sibon, Karsten Nysom, Nathalie Garnier, Stéphane Ducassou, Véronique Vergé, Laurence Lamant, Moussa Angokai, Lucie Oberic, Melissa Barbati, Mathieu Simonin, Marlène Pasquet, Marie-Laure Couec, Sandy Amorim, Aurélie Phulpin, Bouabdallah Reda, Yves Reguerre, François-Xavier Gros, Auke Beishuizen, Véronique Minard-Colin

引用次数: 0

查看原文本刊更多论文

nivolumab治疗复发/难治性alk + alcl的2期nivo-alcl研究，用于疾病进展性患者或作为完全缓解后的巩固免疫治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia research 医学-血液学

CiteScore

4.00

自引率

3.70%

发文量

259

审稿时长

1 months

期刊介绍： Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.